Published in Diabetes Care on June 20, 2008
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) (2009) 1.51
Pharmacotherapies for obesity: past, current, and future therapies. J Obes (2010) 1.43
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
The brain and brown fat. Ann Med (2014) 1.02
Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 0.96
Obesity treatment: novel peripheral targets. Br J Clin Pharmacol (2009) 0.95
Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology (2009) 0.94
Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag (2012) 0.88
Present and future: pharmacologic treatment of obesity. J Obes (2011) 0.84
Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) (2012) 0.83
Amylin-mediated control of glycemia, energy balance, and cognition. Physiol Behav (2016) 0.78
Combinations of drugs in the Treatment of Obesity. Pharmaceuticals (Basel) (2010) 0.77
Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care (2011) 0.76
Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One (2013) 0.76
Treatment options for obesity and potential therapies on the horizon. P T (2011) 0.75
Weight considerations in pharmacotherapy for type 2 diabetes. J Obes (2010) 0.75
Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats. Obes Sci Pract (2016) 0.75
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure. Int J Obes Suppl (2016) 0.75
Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med (2005) 5.35
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A (2008) 2.73
Obesity research--limitations of methods, measurements, and medications. JAMA (2006) 1.97
Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med (2005) 1.69
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract (2001) 1.41
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med (2004) 1.34
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care (2003) 1.30
Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology (2006) 1.21
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab (2007) 1.11
Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets (2005) 1.09
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab (2007) 1.09
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia (2005) 1.06
Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol (2007) 1.03
Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs (2004) 0.89
Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev (2008) 0.87
Guidance for the clinical evaluation of weight-control drugs. Crit Rev Food Sci Nutr (2001) 0.83
Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev (2005) 4.14
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A (2008) 2.73
Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr (2009) 2.71
High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.36
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2015) 2.05
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Zonisamide for weight reduction in obese adults. JAMA (2013) 2.00
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care (2002) 1.91
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther (2002) 1.64
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) (2009) 1.51
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.31
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care (2003) 1.30
Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract (2011) 1.23
Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich) (2012) 1.23
Assessing risk factors for obesity between childhood and adolescence: I. Birth weight, childhood adiposity, parental obesity, insulin, and leptin. Pediatrics (2002) 1.23
Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology (2008) 1.23
Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) (2012) 1.23
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol (2003) 1.16
Assessing risk factors for obesity between childhood and adolescence: II. Energy metabolism and physical activity. Pediatrics (2002) 1.14
Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr (2008) 1.12
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab (2007) 1.11
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab (2007) 1.09
Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn (2011) 1.08
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol (2006) 1.02
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res (2004) 1.02
Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) (2009) 0.98
Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology (2007) 0.98
Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years. N Engl J Med (2017) 0.98
Causes of obesity. Abdom Imaging (2012) 0.97
Obesity in 2010: the future of obesity medicine: where do we go from here? Nat Rev Endocrinol (2011) 0.95
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) (2010) 0.93
Plasma adiponectin and endogenous glucose production in humans. Diabetes Care (2003) 0.93
Fiber type-specific determinants of Vmax for insulin-stimulated muscle glucose uptake in vivo. Am J Physiol Endocrinol Metab (2003) 0.92
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res (2011) 0.92
Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. J Clin Pharmacol (2007) 0.89
Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity (Silver Spring) (2007) 0.89
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev (2004) 0.89
Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes (2002) 0.88
The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest (2003) 0.88
Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev (2008) 0.87
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care (2005) 0.86
Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity (Silver Spring) (2013) 0.86
Role of PYK2 in the development of obesity and insulin resistance. Biochem Biophys Res Commun (2005) 0.86
Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes (2004) 0.85
Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res (2002) 0.85
Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. Curr Diab Rep (2002) 0.85
Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. Obesity (Silver Spring) (2007) 0.84
Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. Metabolism (2004) 0.84
Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab (2004) 0.83
Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects. Diabetes (2004) 0.83
Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. Value Health (2010) 0.82
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group IV: prevention/treatment. Circulation (2004) 0.82
Treatment of obesity in 2015. J Cardiopulm Rehabil Prev (2015) 0.82
Rimonabant: new data and emerging experience. Curr Atheroscler Rep (2008) 0.81
It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med (2009) 0.81
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism (2004) 0.78
Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am (2003) 0.78
Managing overweight and obesity in women. Clin Obstet Gynecol (2002) 0.77
Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. Expert Opin Biol Ther (2015) 0.77
The challenge of treating obesity: the endocannabinoid system as a potential target. J Am Diet Assoc (2008) 0.76
Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring) (2015) 0.76
Implantable gastric stimulator does not prevent the increase in plasma ghrelin levels that occurs with weight loss. Obesity (Silver Spring) (2011) 0.76
Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord (2002) 0.76
Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. Curr Atheroscler Rep (2012) 0.75
The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors. Evid Based Med (2011) 0.75
Relation between physical activity and obesity. Am J Clin Nutr (2003) 0.75
Pharmacotherapy for obesity. Curr Atheroscler Rep (2007) 0.75
Leber's hereditary optic neuropathy: a case report. Optometry (2005) 0.75
Effect of cortisol on muscle sympathetic nerve activity in Pima Indians and Caucasians. J Clin Endocrinol Metab (2003) 0.75
Medical assessment of obese older patients. Clin Geriatr Med (2005) 0.75
The problem of obesity in the United States has become increasingly prominent and is now recognized as a critical target for public health intervention. Introduction. Am J Med (2009) 0.75